Sec Form 4 Filing - Shacham Sharon @ Karyopharm Therapeutics Inc. - 2020-01-08

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Shacham Sharon
2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
President & CSO
(Last) (First) (Middle)
C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE
3. Date of Earliest Transaction (MM/DD/YY)
01/08/2020
(Street)
NEWTON, MA02459
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/08/2020 M( 1 ) 10,000 A $ 4.752 753,506 ( 2 ) D
Common Stock 01/08/2020 S( 1 ) 10,000 D $ 18.5705 ( 3 ) 743,506 D
Common Stock 01/09/2020 M( 4 ) 10,000 A $ 4.752 552,139 ( 5 ) I By Spouse
Common Stock 01/09/2020 S( 4 ) 10,000 D $ 19.188 ( 6 ) 542,139 I By Spouse
Common Stock 12/19/2019 G V 17,313 D $ 0 0 I By GRAT ( 7 )
Common Stock 12/19/2019 G V 17,313 D $ 0 0 I By Spouse's GRAT ( 8 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 4.752 01/08/2020 M( 1 ) 10,000 ( 9 ) 09/02/2023 Common Stock 10,000 $ 0 430,303 D
Stock Option (right to buy) $ 4.752 01/09/2020 M( 4 ) 10,000 ( 9 ) 09/02/2023 Common Stock 10,000 $ 0 386,061 I By Spouse
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Shacham Sharon
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON, MA02459
President & CSO
Signatures
/s/Christopher B. Primiano, Attorney-in-Fact for Sharon Shacham 01/10/2020
Signature of Reporting Person Date
Explanation of Responses:
( 1 )These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
( 2 )Reflects the transfer of 12,372 shares from the Sharon Shacham 2016 Qualified Annuity Trust (the "GRAT") to the reporting person on December 12, 2019.
( 3 )Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.34 to $18.82, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
( 4 )These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
( 5 )Reflects the transfer of 12,372 shares from the Michael G. Kauffman 2016 Qualified Annuity Trust (the "Spouse's GRAT") to the spouse of the reporting person on December 12, 2019.
( 6 )Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.885 to $19.34, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
( 7 )Upon termination of the GRAT, 17,313 shares held by the GRAT were transferred to a trust, the beneficiaries of which share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by such individuals, and this report should not be deemed an admission that the reporting person is the beneficial owner of such individuals' shares for purposes of Section 16 or for any other purpose.
( 8 )Upon termination of the Spouse's GRAT, 17,313 shares held by the Spouse's GRAT were transferred to a trust, the beneficiaries of which share the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by such individuals, and this report should not be deemed an admission that the reporting person is the beneficial owner of such individuals' shares for purposes of Section 16 or for any other purpose.
( 9 )This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.